Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

New Approaches to Using FEIBA in the Treatment of Inhibitor Patients.

Berntorp, Erik LU ; Gringeri, Alessandro ; Leissinger, Cindy ; Négrier, Claude and Key, Nigel (2006) In Seminars in Thrombosis and Hemostasis 32(Suppl 2). p.22-27
Abstract
Managing hemophilia becomes particularly difficult in patients with inhibitory antibodies, especially in those requiring surgery or with refractory bleeding events. Equally challenging are those patients who develop autoantibodies against factor VIII (FVIII) in the absence of a prior history of FVIII deficiency (acquired hemophilia). Physicians seeking both short- and long-term treatment strategies for bleeding events must often rely on FVIII-bypassing agents such as activated prothrombin complex concentrate (e.g., factor eight bypassing activity [FEIBA VH, Baxter BioScience, Westlake Village, CA]) or recombinant factor VIIa (rFVIIa [NovoSeven, NovoNordisk, Bagsvaerd, Denmark]). Surgical procedures in patients with inhibitors present a... (More)
Managing hemophilia becomes particularly difficult in patients with inhibitory antibodies, especially in those requiring surgery or with refractory bleeding events. Equally challenging are those patients who develop autoantibodies against factor VIII (FVIII) in the absence of a prior history of FVIII deficiency (acquired hemophilia). Physicians seeking both short- and long-term treatment strategies for bleeding events must often rely on FVIII-bypassing agents such as activated prothrombin complex concentrate (e.g., factor eight bypassing activity [FEIBA VH, Baxter BioScience, Westlake Village, CA]) or recombinant factor VIIa (rFVIIa [NovoSeven, NovoNordisk, Bagsvaerd, Denmark]). Surgical procedures in patients with inhibitors present a considerable challenge, from both a risk-benefit and a cost-benefit aspect. Hemostasis is difficult to achieve in these patients and new treatment options are being explored. Similarly challenging are refractory bleeds, the management of which is likely to benefit from a systematic treatment approach. (Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Autoantibodies - acquired hemophilia - FVIII-bypassing agents - refractory bleeds - surgery
in
Seminars in Thrombosis and Hemostasis
volume
32
issue
Suppl 2
pages
22 - 27
publisher
Georg Thieme Verlag KG
external identifiers
  • wos:000238852400005
  • scopus:33745714511
ISSN
1098-9064
DOI
10.1055/s-2006-946911
language
English
LU publication?
yes
id
bb529c58-0e2a-4890-94b8-aa8558de7b5c (old id 158071)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16804832&dopt=Abstract
date added to LUP
2016-04-01 15:29:41
date last changed
2020-01-12 18:31:37
@article{bb529c58-0e2a-4890-94b8-aa8558de7b5c,
  abstract     = {Managing hemophilia becomes particularly difficult in patients with inhibitory antibodies, especially in those requiring surgery or with refractory bleeding events. Equally challenging are those patients who develop autoantibodies against factor VIII (FVIII) in the absence of a prior history of FVIII deficiency (acquired hemophilia). Physicians seeking both short- and long-term treatment strategies for bleeding events must often rely on FVIII-bypassing agents such as activated prothrombin complex concentrate (e.g., factor eight bypassing activity [FEIBA VH, Baxter BioScience, Westlake Village, CA]) or recombinant factor VIIa (rFVIIa [NovoSeven, NovoNordisk, Bagsvaerd, Denmark]). Surgical procedures in patients with inhibitors present a considerable challenge, from both a risk-benefit and a cost-benefit aspect. Hemostasis is difficult to achieve in these patients and new treatment options are being explored. Similarly challenging are refractory bleeds, the management of which is likely to benefit from a systematic treatment approach.},
  author       = {Berntorp, Erik and Gringeri, Alessandro and Leissinger, Cindy and Négrier, Claude and Key, Nigel},
  issn         = {1098-9064},
  language     = {eng},
  number       = {Suppl 2},
  pages        = {22--27},
  publisher    = {Georg Thieme Verlag KG},
  series       = {Seminars in Thrombosis and Hemostasis},
  title        = {New Approaches to Using FEIBA in the Treatment of Inhibitor Patients.},
  url          = {http://dx.doi.org/10.1055/s-2006-946911},
  doi          = {10.1055/s-2006-946911},
  volume       = {32},
  year         = {2006},
}